Equity Overview
Price & Market Data
Price: $0.0₃1
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $4,262
Volume: 0
Performance Metrics
1 Week: -50.00%
1 Month: -95.00%
3 Months: %
6 Months: %
1 Year: 9,900%
YTD: 9,900%
Details
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.